Weimin Wang
Founder & Chief Executive Officer Sanegene Bio
Weimin Wang is the Founder and CEO of SanegeneBio, a company dedicated to developing innovative RNA-based therapeutics. A seasoned leader in the field, he brings over two decades of experience from prominent roles at Dicerna Pharmaceuticals and Merck. His extensive expertise spans RNA drug discovery and development, having contributed to the advancement of this modality from its early stages. Dr. Wang holds a PhD in Chemistry from Rutgers University and a BS from Peking University.
Seminars
- Novel ligand-mediated approaches for selectively targeting adipocytes, muscle, and other metabolic compartments are needed to realize the potential of RNAi for obesity therapy
- LEADTM technology is a new ligand-and-enhancer conjugation approach that enables improved specificity and potency for obesity targets across multiple biological mechanisms
- In this presentation, we will share clinical and preclinical data demonstrating the potential for best-in-class RNAi payloads, differentiated pharmaceutical properties, and therapeutic proof-of-concept to treat obesity and metabolic disorders
The breakthroughs in RNAi delivery are no longer confined to the liver, with a new generation of platforms, from antibody conjugates and DNA nanostructures to novel ligands and chemical modifications, enabling precise targeting of metabolic, muscular, and renal tissues. This roundtable unites pioneers to discuss:
- Weighing the advantages of modular platforms against bespoke conjugate strategies for specific tissue targets, considering factors like valency, manufacturability, and immunogenicity.
- Addressing the unique synthesis, characterization, and manufacturing challenges of complex delivery modalities to ensure quality, stability, and scalability for clinical and commercial supply.
- Strategizing on how to design platforms with inherent adaptability to rapidly retarget new tissues and diseases, maximizing platform value and accelerating development timelines.
- n selection for optimal risk/reward, ensuring portfolio companies can attract pharma partnerships or IPO success
